⌘K
Loading ticker…
As of 2026-08-24, Metagenomi Therapeutics, Inc. Common Stock (MGX) has a 3-month relative strength percentile of 30 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.0%, relative volume 1.59×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MGX is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -1.3% / -17.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
MGX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $993K notional.
Held by 3 ETFs · $2M across latest filings · largest weight 0.01% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $993K | — |
| VXFVanguard Extended Market ETF | 0.00% | $424K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MGX Jan avg: -15.21% median: -15.21% win: 0% σ: 14.53% n: 2 2024-02-12 → 2026-07-31 | MGX Feb avg: -3.35% median: -1.30% win: 33% σ: 19.49% n: 3 2024-02-12 → 2026-07-31 | MGX Mar avg: -18.85% median: -11.84% win: 0% σ: 12.83% n: 3 2024-02-12 → 2026-07-31 | MGX Apr avg: -1.09% median: 2.99% win: 67% σ: 30.54% n: 3 2024-02-12 → 2026-07-31 | MGX May avg: -4.10% median: -1.73% win: 0% σ: 4.35% n: 3 2024-02-12 → 2026-07-31 | MGX Jun avg: -20.50% median: -12.94% win: 0% σ: 13.47% n: 3 2024-02-12 → 2026-07-31 | MGX Jul avg: 16.83% median: 0.00% win: 33% σ: 33.49% n: 3 2024-02-12 → 2026-07-31 | MGX Aug avg: -23.90% median: -23.90% win: 0% σ: 0.63% n: 2 2024-02-12 → 2026-07-31 (current) | MGX Sep avg: 4.63% median: 4.63% win: 50% σ: 44.65% n: 2 2024-02-12 → 2026-07-31 | MGX Oct avg: -1.02% median: -1.02% win: 50% σ: 11.59% n: 2 2024-02-12 → 2026-07-31 | MGX Nov avg: -13.01% median: -13.01% win: 50% σ: 25.58% n: 2 2024-02-12 → 2026-07-31 | MGX Dec avg: 33.48% median: 33.48% win: 50% σ: 57.86% n: 2 2024-02-12 → 2026-07-31 |